Given their success in the relapse setting, anti‐PD1 agents are currently being explored in the newly‐diagnosed setting8, 9; therefore, it is expected that more patients affected by HL will be exposed to PD1 inhibitors in the future and thus any information regarding their long‐term outcomes is essential. This evidence concerns the gene PDCD1 and Hodgkins lymphoma.